The content on this site is intended for healthcare professionals only
Dr Sindhuja Kadambi speaks to ecancer about enzalutamide with 5-alpha-reductase inhibitors (5-ARI) for older patients with castration-sensitive systemic prostate cancer.
This study evaluates the effects on fatigue and physical well-being for older adults with prostate cancer who are treated with enzalutamide and 5-alpha-reductase inhibitors.
Geriatric assessments link fatigue to declines in physical health.
The study emphasises the safety of second-generation anti-androgens and the importance of ongoing patient monitoring.
It also highlights the frailty of caregivers, stressing the need for increased support for them.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG
Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity
Intravesical IO using durvalumab shows promising results for patients with high risk NMIBC after BCG failure
Latest in PARP inhibitors and combination therapies for prostate cancer
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
